ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sarilumab

Also written as “Sarilumab”, “REGN88” and “sarilumab SAR153191 (REGN88)”.

Its studies are mostly in Arthritis, Rheumatoid · Polymyalgia Rheumatica · Arthritis, Juvenile · Spondylitis, Ankylosing · Coronavirus Infections, led by 2 companies.

Drug pageSarilumab: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 8, 201827 company-led studies, 3 open or runningNext primary completion: Mar 1, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi223 open or runningphase 4since Feb 8, 2018Feb 2, 2010Mar 1, 2028phase 2 · NCT02991469
Regeneron Pharmaceuticalsits history only50 open or runningphase 3since Mar 15, 2020Nov 10, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Feb 2, 2010.

  1. Jan 8, 20132 phase 3 studies in Arthritis, RheumatoidNCT01764997, NCT01768572
  2. Jul 11, 2013Phase 2 study in UveitisNCT01900431 · 58 enrolled · United States, Czechia, France and more
  3. Apr 21, 2014Phase 3 study in Arthritis, RheumatoidNCT02121210 · 132 enrolled · United States, Chile, Czechia and more
  4. Jan 5, 2015Phase 3 study in Arthritis, RheumatoidNCT02332590 · 369 enrolled · United States, Chile, Czechia and more
  5. Feb 12, 2015Phase 3 study in Arthritis, RheumatoidNCT02373202 · 91 enrolled · Japan
  6. Mar 26, 2015Phase 1 study in Arthritis, RheumatoidNCT02404558 · 30 enrolled · Japan
  7. May 16, 2016Phase 2 study in Arthritis, JuvenileNCT02776735 · 102 enrolled · United States, Argentina, Canada and more
  8. Oct 14, 2016Phase 2 study in Arthritis, JuvenileNCT02991469 · 51 planned · Argentina, Canada, Finland and more
  9. Feb 8, 2018Phase 4 study in Arthritis, RheumatoidNCT03449758 · 84 enrolled · France
  10. Jul 17, 2018Phase 3 study in Polymyalgia RheumaticaNCT03600818 · 118 enrolled · United States, Argentina, Australia and more
  11. Mar 26, 2020Phase 3 study in Coronavirus InfectionsNCT04327388 · 420 enrolled · Argentina, Brazil, Canada and more
  12. Nov 28, 2023Phase 1 study in Arthritis, RheumatoidNCT06159452 · 53 enrolled
  13. Dec 10, 2025Phase 3 study in Polymyalgia RheumaticaNCT07286214 · 300 planned · United States, Austria, Belgium and more
  14. Jun 22, 2026Phase 2 study in Arthritis, RheumatoidNCT07704580 · 140 planned · United States

Ahead

  1. Mar 1, 2028Primary completion: phase 2 study in Arthritis, JuvenileNCT02991469
  2. Oct 26, 2028Primary completion: phase 2 study in Arthritis, RheumatoidNCT07704580
  3. Jun 4, 2029Primary completion: phase 3 study in Polymyalgia RheumaticaNCT07286214

TargetBeta

IL6R →read by rule
“A recombinant, human immunoglobulin (IgG) monoclonal antibody targeting the interleukin 6 receptor (IL-6R), ”NCIt, by rule
“Interleukin-6 receptor alpha subunit antagonist”ChEMBL 37, by rule

Other programs on IL6R

ProgramCompanyFurthest phaseStudies
tocilizumabruleHoffmann-La Rochephase 4130

Studies

All 22 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07704580Arthritis, Rheumatoid · United States2RecruitingOct 26, 2028140
NCT07286214Polymyalgia Rheumatica · United States, Austria, Belgium and more3RecruitingJun 4, 2029300
NCT06159452Arthritis, Rheumatoid1CompletedDec 21, 201053
NCT04327388Coronavirus Infections · Argentina, Brazil, Canada and more3CompletedJul 31, 2020420
NCT03600818Polymyalgia Rheumatica · United States, Argentina, Australia and more3TerminatedMay 19, 2021118
NCT03449758Arthritis, Rheumatoid · France4CompletedJul 31, 201984
NCT02991469Arthritis, Juvenile · Argentina, Canada, Finland and more2RecruitingMar 1, 202851
NCT02776735Arthritis, Juvenile · United States, Argentina, Canada and more2CompletedApr 8, 2022102
NCT02404558Arthritis, Rheumatoid · Japan1CompletedMar 201630
NCT02373202Arthritis, Rheumatoid · Japan3CompletedNov 201691
NCT02332590Arthritis, Rheumatoid · United States, Chile, Czechia and more3CompletedJan 20, 2016369
NCT02121210Arthritis, Rheumatoid · United States, Chile, Czechia and more3CompletedMay 2015132
NCT01900431Uveitis · United States, Czechia, France and more2CompletedJul 201558
NCT01768572Arthritis, Rheumatoid · United States, Argentina, Belgium and more3CompletedOct 2014202
NCT01764997Arthritis, Rheumatoid · United States, Argentina, Australia and more3TerminatedJan 2015776
NCT01709578Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedMar 2015546
NCT01328522Arthritis, Rheumatoid · United States1CompletedSep 201132
NCT01217814Arthritis, Rheumatoid · United States, Colombia, Czechia and more2TerminatedSep 201116
NCT01146652Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedDec 31, 20202,023
NCT01118728Spondylitis, Ankylosing · United States, Australia, Austria and more2TerminatedDec 2011223
NCT01061736Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedOct 20131,675
NCT01061723Spondylitis, Ankylosing · United States, Australia, Austria and more2CompletedJun 2011301

How it is read

Names in the registry

  • “Sarilumab”, 14 entries
  • “REGN88”, 5 entries
  • “sarilumab SAR153191 (REGN88)”, 3 entries
  • “Sarilumab SAR153191 (REGN88)”, 2 entries
  • “SAR153191 (REGN88)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.